Director General of Pharma Bio LLC presenting the company’s products at Innovation Day 2015

 
 

We have set for ourselves an ambitious goal of creating an independent and high-tech domestic production of pharmaceutical substances and peptide drugs. Achieving this goal will help patients with socially significant diseases to use the most modern international standards of drug therapy.

Our pipeline currently consists of the following drugs:

  • Timodepressin – immunosuppressant, a drug for the treatment of autoimmune diseases: psoriasis, atopic dermatitis, rheumatoid arthritis, etc. On the market in Russia. Details on the website http://timodepressin.ru

 
 

A patient before and after treatment with Timodepressin
  • Stemokin - a drug to stimulate hematopoiesis and immunity after exposure to chemotherapy and radiation, as well as for the treatment of secondary immunodeficiency conditions. On the market in Russia.
  • IBCH-05 - anxiolytic, stress-protector, a drug for the treatment and prevention of anxiety disorders; successfully passed Phase I clinical trials, currently in Phase II clinical trials.
  • IBCH-07 - an anti-alcoholism drug; successfully passed Phase I clinical trials, currently in Phase II clinical trials.
  • C12 – a drug for the prevention and treatment of Alzheimer’s disease; currently in pre-clinical studies.
  • Immunostaining of beta-amyloid in the cerebral cortex of control (photo A) and C12-treated (photo B) transgenic mice. Beta-amyloid in brown.

     

    Immunostaining of phosphorylated tau protein in the cerebral cortex of control (photo A) and C12-treated (photo B) transgenic mice. Tau protein in brown.